In this study, we demonstrated that short-term administration of MCS to breast cancer cells with p53 mutations not only induces cell death specifically in cancer cells but also enhances the efficacy of 5-FU, potentially providing adequate tumor growth suppression at low doses. Here, TP53 is linked to breast carcinoma.